Kathryn Sullivan, MD
Urology · Travis Afb, CANPI 1487700167
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $727 and has fallen 97.1% since, to $21 in 2024. That places this record below the midpoint for urology clinicians in CA, where the typical reported total is $2,485.
Across 126 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$338
- Johnson & Johnson$272
- Astellas Pharma US Inc$193
- Urogen Pharma, Inc.$155
- Pfizer$154
- Tolmar Pharmaceuticals, Inc.$114
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,21899%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $338 |
| Johnson & Johnson(2 entities) | 16 | $272 |
| Astellas Pharma US Inc | 12 | $193 |
| Urogen Pharma, Inc. | 7 | $155 |
| Pfizer | 10 | $154 |
| Tolmar Pharmaceuticals, Inc. | 6 | $114 |
| Urovant Sciences Inc | 4 | $89 |
| Amgen | 4 | $79 |
| Antares Pharma, Inc. | 4 | $76 |
| Endo Pharmaceuticals Inc. | 4 | $72 |
| Rochester Medical Corporation | 5 | $71 |
| Acerus Pharmaceuticals Corporation | 4 | $71 |
| Olympus America Inc. | 3 | $68 |
| Blue Earth Diagnostics | 3 | $63 |
| Myovant Sciences Inc. | 3 | $52 |
| Myriad Genetic Laboratories, Inc. | 3 | $50 |
| Coloplast | 3 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Boston Scientific | 3 | $40 |
| Axonics, Inc. | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Sanofi | 1 | $24 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $20 |
| Tolmar, Inc. | 1 | $20 |
| Novartis | 1 | $16 |
| Vyera Pharmaceuticals, LLC | 1 | $16 |
| Clarus Therapeutics Inc. | 1 | $16 |
| Convatec Inc. | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $13 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,250 in reported general payments places this provider in the 45th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 11 | $988 |
| Solifenacin Succinate | 14 | $386 |
| Tamsulosin Hcl | 27 | $322 |
| Finasteride | 12 | $245 |
| Hydrochlorothiazide | 12 | $11 |
Paid to pharmacies, not to this prescriber.
Other urology in Travis Afb
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
- William AronsonLos Angeles$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.